Abstract | PURPOSE: METHODS: This retrospective, single-center study included 146 patients who received 7 + 3 induction ( cytarabine and anthracycline) for treatment of AML. Study design evaluated the relationship between percentage of ABW dosing and complete response (CR) rates in patients newly diagnosed with AML. RESULTS: Percentage of ABW dosing did not influence CR rates in patients undergoing induction chemotherapy for AML (p = 0.83); nor did it influence rate of death at 30 days or relapse at 6 months (p = 0.94). When comparing patients dosed at 90-100 % of ABW compared to <90 % ABW, CR rates were not significantly different in patients classified as poor risk (p = 0.907). All favorable risk category patients obtained CR. CONCLUSIONS:
|
Authors | Whitney M Bray, Cory Bivona, Michelle Rockey, Dave Henry, Dennis Grauer, Sunil Abhyankar, Omar Aljitawi, Siddhartha Ganguly, Joseph McGuirk, Anurag Singh, Tara L Lin |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 76
Issue 4
Pg. 691-7
(Oct 2015)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 26231954
(Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Anthracyclines
- Antineoplastic Agents
- Cytarabine
|
Topics |
- Adult
- Aged
- Anthracyclines
(administration & dosage, therapeutic use)
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Body Mass Index
- Body Weight
- Cohort Studies
- Cytarabine
(administration & dosage, therapeutic use)
- Drug Dosage Calculations
- Drug Resistance, Neoplasm
- Female
- Follow-Up Studies
- Humans
- Induction Chemotherapy
- Leukemia, Myeloid, Acute
(complications, drug therapy, mortality, prevention & control)
- Male
- Middle Aged
- Obesity
(complications)
- Overweight
(complications)
- Recurrence
- Remission Induction
- Retrospective Studies
- Young Adult
|